RI
CLDX icon

RTW Investments’s Celldex Therapeutics CLDX Stock Holding History

RTW Investments’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,463,201
Closed -$137M – 72
2023
Q4 		$137M Hold
3,463,201
– – 2.15% 17
2023
Q3 		$95.3M Hold
3,463,201
– – 2.01% 18
2023
Q2 		$118M Buy
3,463,201
+378,986
+12% +$12.8M 2.24% 18
2023
Q1 		$111M Hold
3,084,215
– – 2.31% 16
2022
Q4 		$137M Hold
3,084,215
– – 2.81% 14
2022
Q3 		$86.7M Hold
3,084,215
– – 2% 17
2022
Q2 		$83.2M Hold
3,084,215
– – 2.15% 15
2022
Q1 		$105M Sell
3,084,215
-837,364
-21% -$26.8M 2.17% 18
2021
Q4 		$152M Buy
3,921,579
+12,632
+0.3% +$550K 2.21% 14
2021
Q3 		$211M Hold
3,908,947
– – 3.18% 8
2021
Q2 		$131M Hold
3,908,947
– – 1.97% 14
2021
Q1 		$80.5M Buy
3,908,947
+486,092
+14% +$11.2M 1.26% 27
2020
Q4 		$60M Buy
3,422,855
+302,718
+10% +$5.45M 1.01% 30
2020
Q3 		$46.3M Buy
3,120,137
+510,137
+20% +$5.98M 1.11% 27
2020
Q2 		$33.9M Buy
+2,610,000
New +$11.6M 0.95% 32
2017
Q2 		– Sell
-16,113
Closed -$873K – 29
2017
Q1 		$873K Buy
16,113
+136
+0.9% +$7.08K 0.23% 24
2016
Q4 		$848K Sell
15,977
-66,901
-81% -$3.81M 0.32% 23
2016
Q3 		$5.02M Sell
82,878
-1,404
-2% -$87.4K 1.52% 18
2016
Q2 		$5.55M Buy
84,282
+18,324
+28% +$1.16M 1.9% 17
2016
Q1 		$3.74M Buy
65,958
+23,475
+55% +$2.64M 1.36% 18
2015
Q4 		$9.99M Sell
42,483
-5,432
-11% -$1.18M 3.25% 12
2015
Q3 		$7.58M Buy
47,915
+16,478
+52% +$4.66M 2.35% 14
2015
Q2 		$11.9M Buy
+31,437
New +$12.5M 3.46% 13

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RTW Investments's CLDX Position: Q1 2024 in Review

RTW Investments sold out of Celldex Therapeutics (CLDX) in Q1 2024, closing a stake of 3,463,201 shares — an estimated $137M sold.

RTW Investments first reported a position in CLDX in Q2 2015 and held it in 23 quarters. The position peaked at $211M in Q3 2021. 197 funds tracked by Wall St. Rank hold CLDX as of Q1 2024.

  • RTW Investments reported no remaining Celldex Therapeutics position as of Q1 2024 after selling out during the quarter.
  • RTW Investments sold 3,463,201 Celldex Therapeutics shares in Q1 2024, an estimated $137M.
  • RTW Investments first reported a position in Celldex Therapeutics in Q2 2015 and held it in 23 quarters.
  • RTW Investments's Celldex Therapeutics position peaked at $211M in Q3 2021.
  • 197 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2024.

Based on RTW Investments's 13F filing for Q1 2024, filed 15 May 2024.